CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies - Scorecard - MDSpire
Advertisement
CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies
Clinical Scorecard: Exploring the Role of CD169-Positive Macrophages in Lymph Nodes and Tumor Microenvironments: Implications for Clinical Diagnosis and Cancer Treatment Strategies
At a Glance
Category
Detail
Condition
CD169+ macrophages in cancer
Key Mechanisms
Regulation of immune responses and tumor progression in tumor-draining lymph nodes and tumor microenvironment.
Target Population
Patients with solid tumors.
Care Setting
Oncology and immunotherapy.
Key Highlights
CD169+ macrophages are critical in shaping antitumor immunity.
High densities of CD169+ macrophages in tdLNs correlate with improved survival outcomes.
CD169+ macrophages serve as prognostic and predictive biomarkers in cancer.
Their roles are context-dependent, influenced by tumor type and microenvironment.
Immunotherapeutic strategies targeting CD169+ macrophages may enhance antitumor responses.
Guideline-Based Recommendations
Diagnosis
Evaluate CD169+ macrophage density in tumor-draining lymph nodes as a prognostic indicator.
Management
Consider immunotherapeutic strategies that target CD169+ macrophages to improve treatment outcomes.
Monitoring & Follow-up
Monitor changes in CD169+ macrophage populations in response to treatment.
Risks
Potential for context-dependent effects of CD169+ macrophages on tumor progression.
Patient & Prescribing Data
Patients with various solid tumors.
Targeting CD169+ macrophages may provide new avenues for enhancing antitumor immunity.
Clinical Best Practices
Integrate assessment of CD169+ macrophages in clinical staging of tumors.
Utilize CD169+ macrophage density as a biomarker for patient prognosis.
